Oral PCSK9 inhibitor, AZD0780 demonstrates significant Reduction of LDL-C in Hypercholesterolemia patients in phase 1 trial Dr. Kamal Kant Kohli5 Jun 2024 10:00 AM ISTPositive results from a Phase I trial of AZD0780, an oral small molecule PCSK9 inhibitor administered on top of statin treatment, were presented at...
Alirocumab addition to statins fails to improve endothelial function in acute MI patients: PACMAN-AMI trial substudy Medha Baranwal15 May 2024 10:00 AM ISTSwitzerland: In a significant development in cardiovascular medicine, findings from a substudy of the PACMAN-AMI randomized clinical trial shed light...
REMAIN-2 Trial reveals long-term safety and efficacy of recaticimab in patients with non-FH and mixed hyperlipidemia Medha Baranwal30 Nov 2023 10:30 AM ISTChina: A recent study has shown the long-term efficacy and safety of add-on recaticimab as a treatment option in patients with non-familial...
PCSK9 inhibitors act through plaque stabilisation not by improving coronary physiology: PACMAN-AMI trial Medha Baranwal13 July 2023 10:15 AM ISTSwitzerland: Acute myocardial infarction (AMI) patients treated with alirocumab had a significant regression in angiographic diameter stenosis (DS%)....
Long-term use of evolocumab tied to sustained reduction of LDL C and CV events: FOURIER-OLE trial Dr. Kamal Kant Kohli3 Sept 2022 11:00 AM ISTEvolocumab is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used to lower CVD risk by controlling LDL cholesterol.According to...
Journal Club - Smokers With Heart Disease can add up 5 Years by Quitting Dr. Nandita Mohan4 May 2022 6:36 PM ISTAdverse effects of smoking and heart health in smokers. Smoking cessation appears to be comparable to the use of three targeted drugs in warding off...
Alirocumab addition to statins significantly regresses plaque in non infarct-related coronary arteries MD Bureau22 April 2022 9:00 AM ISTStatins have been shown to reduce cardiovascular adverse events in patients with atherosclerotic disease. In a recent study, researchers have reported...
Oral PCSK9 to drop LDL levels low Dr. Nandita Mohan6 Dec 2021 5:50 PM ISTLow-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits...
Oral PCSK9 inhibitor may significantly reduce LDL C levels: DALLAS, The First Human Trial Dr. Prem Aggarwal3 Dec 2021 2:07 PM ISTLow-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits...
Evolocumab Improves Features Of Plaque Stability In patients of ACS: HUYGENS trial Medical Dialogues Bureau30 Aug 2021 6:15 AM ISTUSA: Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features...
PCSK9 inhibitor Evinacumab may significantly lower LDL cholesterol in FH: NEJM Medha Baranwal21 Aug 2020 11:30 AM ISTDelhi: Evinacumab significantly lowers LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum...
PCSK9 inhibitors may improve function of coronary arteries also: JAHA study Dr. Kamal Kant Kohli30 July 2020 8:30 PM ISTResearchers at Johns Hopkins Medicine have found in a pilot study that a six-week course of a cholesterol-lowering medication improved the function of...
